Fred Alger Management, LLC Tg Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $1.57 Million - $2.92 Million	-72,209 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $100,555 - $151,482	-3,094 Reduced 4.11%	72,209 $2.8 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $488,875 - $637,970	-11,749 Reduced 13.5%	75,303 $3.63 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $525,060 - $1.14 Million	20,778 Added 31.35%	87,052 $4.53 Million
Q3 2020 Nov 13, 2020	SELL	$18.49 - $27.24 $161,343 - $237,696	-8,726 Reduced 11.63%	66,274 $1.77 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $302,600 - $742,560	34,000 Added 82.93%	75,000 $1.46 Million
Q1 2020 May 15, 2020	BUY	$7.14 - $15.99 $292,740 - $655,590	41,000 New	41,000 $403,000

340

88.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.09B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.